{"transactions":[{"id":4626229,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Common Shares","published_at":"2026-09-24T20:40:34.000Z","date":"2026-09-22","kind":"purchase","planned":false,"acquired":true,"shares":5102,"price":1.97,"value":10050.94,"ownership":{"direct":true},"balance_after":5102,"source":{"system":"sec-edgar","filing":"0001552781-26-000501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000155278126000501/ownership.xml","form_type":"4"}},{"id":733854,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":20313,"kind":"person","name":"Astley-Sparke Philip","position":1,"cik":"0001376491","reported_name":"Astley-Sparke Philip","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:44:19.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002263","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376491/000092963826002263/form4.xml","form_type":"4"}},{"id":733565,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37163,"kind":"person","name":"BRUNK GERALD A","position":1,"cik":"0001380226","reported_name":"BRUNK GERALD A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:43:06.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002262","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380226/000092963826002262/form4.xml","form_type":"4"}},{"id":733585,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:41:35.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002261","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963826002261/form4.xml","form_type":"4"}},{"id":733219,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:40:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company."}],"balance_after":200000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000929638-26-002260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963826002260/form4.xml","form_type":"4"}},{"id":733218,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true,"officer":true,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:40:43.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963826002260/form4.xml","form_type":"4"}},{"id":733614,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":36279,"kind":"person","name":"HASTINGS PAUL J","position":1,"cik":"0001309702","reported_name":"HASTINGS PAUL J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:39:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002259","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309702/000092963826002259/form4.xml","form_type":"4"}},{"id":733980,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:38:11.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002258","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448914/000092963826002258/form4.xml","form_type":"4"}},{"id":735093,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37454,"kind":"person","name":"Joustra Wouter","position":1,"cik":"0001897813","reported_name":"Joustra Wouter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:37:15.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002257","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897813/000092963826002257/form4.xml","form_type":"4"}},{"id":733638,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37177,"kind":"person","name":"Zoth Lota S.","position":1,"cik":"0001278219","reported_name":"Zoth Lota S.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T21:35:34.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders."}],"balance_after":31000,"derivative":{"exercise_price":1.75,"expiration_date":"2036-06-16","underlying":"Common Shares","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0000929638-26-002256","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278219/000092963826002256/form4.xml","form_type":"4"}},{"id":920713,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:13:44.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000484","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963826000484/form4.xml","form_type":"4"}},{"id":920712,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67857,"kind":"person","name":"Nichols Alexander Julian","position":1,"cik":"0001998744","reported_name":"Nichols Alexander Julian","relationship":{"officer":true,"officer_title":"Chief Strategy & Ops. Ofc"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:11:10.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000482","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963826000482/form4.xml","form_type":"4"}},{"id":920974,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:08:55.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":801000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":801000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":801000},"source":{"system":"sec-edgar","filing":"0000929638-26-000480","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963826000480/form4.xml","form_type":"4"}},{"id":920754,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:12:56.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000483","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963826000483/form4.xml","form_type":"4"}},{"id":921044,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67903,"kind":"person","name":"Daws D. Ryan","position":1,"cik":"0001598602","reported_name":"Daws D. Ryan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:10:07.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":220000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0000929638-26-000481","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598602/000092963826000481/form4.xml","form_type":"4"}},{"id":922355,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67998,"kind":"person","name":"Connolly Joan","position":1,"cik":"0002041481","reported_name":"Connolly Joan","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:07:21.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000479","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041481/000092963826000479/form4.xml","form_type":"4"}},{"id":922439,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":68003,"kind":"person","name":"Boyd Matthew Ross","position":1,"cik":"0002077001","reported_name":"Boyd Matthew Ross","relationship":{"officer":true,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:06:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000478","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077001/000092963826000478/form4.xml","form_type":"4"}},{"id":920879,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67874,"kind":"person","name":"Buck Jill","position":1,"cik":"0001780426","reported_name":"Buck Jill","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T16:05:51.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":195000,"derivative":{"exercise_price":9.53,"expiration_date":"2036-01-30","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0000929638-26-000477","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1780426/000092963826000477/form4.xml","form_type":"4"}},{"id":1028981,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":74728,"kind":"person","name":"Sweiti Hussein","position":1,"cik":"0002088436","reported_name":"Sweiti Hussein","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T20:54:55.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on September 29, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service."}],"balance_after":600000,"derivative":{"exercise_price":6.83,"expiration_date":"2035-09-30","underlying":"Common Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0000929638-25-003710","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963825003710/form4.xml","form_type":"4"}},{"id":1088155,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":68003,"kind":"person","name":"Boyd Matthew Ross","position":1,"cik":"0002077001","reported_name":"Boyd Matthew Ross","relationship":{"officer":true,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-14T16:10:07.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":100000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000929638-25-002586","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077001/000092963825002586/form4.xml","form_type":"4"}},{"id":1089219,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":20313,"kind":"person","name":"Astley-Sparke Philip","position":1,"cik":"0001376491","reported_name":"Astley-Sparke Philip","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-10T20:07:16.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of Mr. Astley-Sparke's date of appointment to the Board, which was July 8, 2025."}],"balance_after":45000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000929638-25-002558","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376491/000092963825002558/form4.xml","form_type":"4"}},{"id":1089245,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-10T20:06:43.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of Mr. Heffernan's date of appointment to the Board, which was July 8, 2025."}],"balance_after":45000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000929638-25-002557","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448914/000092963825002557/form4.xml","form_type":"4"}},{"id":1089044,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37103,"kind":"person","name":"Grossman William","position":1,"cik":"0001730229","reported_name":"Grossman William","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-10T20:06:13.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of Dr. Grossman's date of appointment to the Board, which was July 8, 2025."}],"balance_after":45000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000929638-25-002556","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730229/000092963825002556/form4.xml","form_type":"4"}},{"id":1089041,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67874,"kind":"person","name":"Buck Jill","position":1,"cik":"0001780426","reported_name":"Buck Jill","relationship":{"officer":true,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-10T16:05:13.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":100000,"derivative":{"exercise_price":3.83,"expiration_date":"2035-07-08","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000929638-25-002554","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1780426/000092963825002554/form4.xml","form_type":"4"}},{"id":1109567,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37177,"kind":"person","name":"Zoth Lota S.","position":1,"cik":"0001278219","reported_name":"Zoth Lota S.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:40:38.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002253","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278219/000092963825002253/form4.xml","form_type":"4"}},{"id":1110436,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37454,"kind":"person","name":"Joustra Wouter","position":1,"cik":"0001897813","reported_name":"Joustra Wouter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:39:30.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002251","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897813/000092963825002251/form4.xml","form_type":"4"}},{"id":1109561,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":36279,"kind":"person","name":"HASTINGS PAUL J","position":1,"cik":"0001309702","reported_name":"HASTINGS PAUL J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:38:50.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders.."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002250","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309702/000092963825002250/form4.xml","form_type":"4"}},{"id":1109517,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:38:11.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002249","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963825002249/form4.xml","form_type":"4"}},{"id":1109509,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37163,"kind":"person","name":"BRUNK GERALD A","position":1,"cik":"0001380226","reported_name":"BRUNK GERALD A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:37:39.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\").  Mr. Brunk expressly disclaims beneficial ownership of these securities."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002248","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380226/000092963825002248/form4.xml","form_type":"4"}},{"id":1109995,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":25488,"kind":"person","name":"Bos Jasper","position":1,"cik":"0001897789","reported_name":"Bos Jasper","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T22:36:59.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders."}],"balance_after":22500,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000929638-25-002247","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897789/000092963825002247/form4.xml","form_type":"4"}},{"id":1109347,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":78428,"kind":"person","name":"Pott Amy","position":1,"cik":"0001787363","reported_name":"Pott Amy","relationship":{"officer":true,"officer_title":"Chief Global Comm. Ofc."}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T18:40:07.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on May 27, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service."}],"balance_after":400000,"derivative":{"exercise_price":3.31,"expiration_date":"2035-06-16","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000929638-25-002252","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787363/000092963825002252/form4.xml","form_type":"4"}},{"id":1289053,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67857,"kind":"person","name":"Nichols Alexander Julian","position":1,"cik":"0001998744","reported_name":"Nichols Alexander Julian","relationship":{"officer":true,"officer_title":"Chief Strategy & Ops. Ofc"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:44:27.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":250000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000929638-25-000480","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963825000480/form4.xml","form_type":"4"}},{"id":1289052,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:38:24.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":250000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000929638-25-000477","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963825000477/form4.xml","form_type":"4"}},{"id":1289121,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:36:39.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":850000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":850000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":850000},"source":{"system":"sec-edgar","filing":"0000929638-25-000476","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963825000476/form4.xml","form_type":"4"}},{"id":1289760,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":83741,"kind":"person","name":"Pruthi Raj Som","position":1,"cik":"0002030291","reported_name":"Pruthi Raj Som","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:46:11.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":280000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000929638-25-000481","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030291/000092963825000481/form4.xml","form_type":"4"}},{"id":1289091,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:42:31.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":250000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000929638-25-000479","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963825000479/form4.xml","form_type":"4"}},{"id":1289149,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67903,"kind":"person","name":"Daws D. Ryan","position":1,"cik":"0001598602","reported_name":"Daws D. Ryan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:40:20.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service."}],"balance_after":280000,"derivative":{"exercise_price":7.39,"expiration_date":"2035-01-29","underlying":"Common Shares","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0000929638-25-000478","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598602/000092963825000478/form4.xml","form_type":"4"}},{"id":1377969,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-11-01T16:15:08.000Z","date":"2024-10-30","kind":"purchase","planned":false,"acquired":true,"shares":561797,"price":8.9,"value":4999993.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 30, 2024, Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\") acquired 561,797 Common Shares in a private placement by the Issuer pursuant to the terms of a Subscription Agreement dated October 24, 2024."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Cooperatief.  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3032430,"source":{"system":"sec-edgar","filing":"0000950170-24-120079","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024120079/ownership.xml","form_type":"4"}},{"id":1382693,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-22T20:08:23.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on October 21, 2025, which is the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years, subject to Dr. Cheung's continued service."}],"balance_after":100000,"derivative":{"exercise_price":9.83,"expiration_date":"2034-10-21","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000929638-24-003559","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963824003559/form4.xml","form_type":"4"}},{"id":1383087,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67998,"kind":"person","name":"Connolly Joan","position":1,"cik":"0002041481","reported_name":"Connolly Joan","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-22T16:07:13.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-qualified stock option grant awarded pursuant to the Employment Agreement dated October 21, 2024 between Ms. Connolly and enGene USA, Inc. as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4).  This option vests at 25% on October 21, 2025, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to Ms. Connolly's continued service."}],"balance_after":210000,"derivative":{"exercise_price":9.83,"expiration_date":"2034-10-21","underlying":"Common Shares","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0000929638-24-003557","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2041481/000092963824003557/form4.xml","form_type":"4"}},{"id":1383919,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-08","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":6.5981,"value":5278.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.59 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2470633,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383918,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-07","kind":"purchase","planned":false,"acquired":true,"shares":11844,"price":6.546,"value":77530.824,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.42 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2469833,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383917,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":5997,"price":6.5436,"value":39241.9692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.50 to $6.62, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2457989,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383916,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":5769,"price":6.4824,"value":37396.9656,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.435 to $6.585, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2451992,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383915,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":10153,"price":6.3722,"value":64696.9466,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.07 to $6.67, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2446223,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383914,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":35279,"price":6.4389,"value":227157.9531,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.30 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2436070,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383913,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-09-30","kind":"purchase","planned":false,"acquired":true,"shares":341332,"price":6.338,"value":2163362.216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.97 to $6.60, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2400791,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383912,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":3243,"price":6.3794,"value":20688.3942,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.31 to $6.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2059459,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383911,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":38396,"price":5.9384,"value":228010.8064,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.31 to $6.30, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2056216,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383910,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":9620,"price":9.0905,"value":87450.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.65 to $9.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2017820,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383909,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":400,"price":8.3,"value":3320.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2008200,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383908,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2023-12-28","kind":"purchase","planned":false,"acquired":true,"shares":5050,"price":7.6885,"value":38826.925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.48 to $8.19, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2007800,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1383907,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":84623,"kind":"organization","name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","position":1,"cik":"0001911047","reported_name":"Forbion Growth Opportunities Fund I Cooperatief U.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84624,"kind":"organization","name":"Forbion Growth Management B.V.","position":2,"cik":"0001918318","reported_name":"Forbion Growth Management B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-10-18T16:15:05.000Z","date":"2023-12-27","kind":"purchase","planned":false,"acquired":true,"shares":2750,"price":7.1678,"value":19711.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.10 to $7.37, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares held by Forbion Growth Opportunities Fund I Cooperatief U.A. (\"Forbion Cooperatief\").  Forbion Growth Management B.V. (\"Forbion Management\") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the \"Management Investment Committee\"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any."}],"balance_after":2002750,"source":{"system":"sec-edgar","filing":"0000950170-24-115607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1911047/000095017024115607/ownership.xml","form_type":"4"}},{"id":1396501,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Shares","published_at":"2024-10-01T12:02:44.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":5.7,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.50 to $5.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000929638-24-003358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963824003358/form4.xml","form_type":"4"}},{"id":1448749,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":83741,"kind":"person","name":"Pruthi Raj Som","position":1,"cik":"0002030291","reported_name":"Pruthi Raj Som","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-25T20:32:45.000Z","date":"2024-07-24","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on July 24, 2025, which is the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years."}],"balance_after":110000,"derivative":{"exercise_price":8.65,"expiration_date":"2034-07-24","underlying":"Common Shares","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0000929638-24-002597","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030291/000092963824002597/form4.xml","form_type":"4"}},{"id":1449187,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":35087,"kind":"person","name":"Cooper Ronald Harold Wilfred","position":1,"cik":"0001676880","reported_name":"Cooper Ronald Harold Wilfred","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-24T22:26:58.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-qualified stock option granted awarded pursuant to the Employment Agreement dated July 22, 2024 between Mr. Cooper and enGene USA, Inc. as an inducement award outside of the enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4).  This option vests at 25% on July 22, 2025, which is the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years, subject to Mr. Cooper's continued service."}],"balance_after":1250000,"derivative":{"exercise_price":8.81,"expiration_date":"2034-07-22","underlying":"Common Shares","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0000929638-24-002577","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1676880/000092963824002577/form4.xml","form_type":"4"}},{"id":1474853,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37177,"kind":"person","name":"Zoth Lota S.","position":1,"cik":"0001278219","reported_name":"Zoth Lota S.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:09:40.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders."}],"balance_after":20000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000929638-24-002217","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278219/000092963824002217/form4.xml","form_type":"4"}},{"id":1474839,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":36279,"kind":"person","name":"HASTINGS PAUL J","position":1,"cik":"0001309702","reported_name":"HASTINGS PAUL J","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:08:51.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of the date vesting commenced, which was May 15, 2024."}],"balance_after":40000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000929638-24-002216","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1309702/000092963824002216/form4.xml","form_type":"4"}},{"id":1476270,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37454,"kind":"person","name":"Joustra Wouter","position":1,"cik":"0001897813","reported_name":"Joustra Wouter","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:08:01.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of the date vesting commenced, which was May 15, 2024."}],"balance_after":40000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000929638-24-002215","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897813/000092963824002215/form4.xml","form_type":"4"}},{"id":1474804,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:06:48.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders."}],"balance_after":20000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000929638-24-002214","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963824002214/form4.xml","form_type":"4"}},{"id":1475740,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":25488,"kind":"person","name":"Bos Jasper","position":1,"cik":"0001897789","reported_name":"Bos Jasper","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:05:02.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders."}],"balance_after":20000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000929638-24-002213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897789/000092963824002213/form4.xml","form_type":"4"}},{"id":1474773,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37163,"kind":"person","name":"BRUNK GERALD A","position":1,"cik":"0001380226","reported_name":"BRUNK GERALD A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-18T20:04:17.000Z","date":"2024-06-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\").  Mr. Brunk expressly disclaims beneficial ownership of these securities."}],"balance_after":20000,"derivative":{"exercise_price":9,"expiration_date":"2034-06-15","underlying":"Common Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000929638-24-002212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380226/000092963824002212/form4.xml","form_type":"4"}},{"id":1498935,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T22:12:54.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":false,"shares":120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This option was originally due to expire December 4, 2023, however prior to that date the expiration date was extended to 120 days following the filing of enGene Holdings Inc.'s Form S-8, which was filed February 27, 2024. Accordingly, the option expiry date is June 26, 2024."}],"balance_after":0,"derivative":{"exercise_price":0.89,"underlying":"Common Shares","underlying_shares":120},"source":{"system":"sec-edgar","filing":"0000929638-24-002002","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963824002002/form4.xml","form_type":"4"}},{"id":1498934,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-05-29T22:12:54.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":true,"shares":120,"price":0.89,"value":106.8,"ownership":{"direct":true},"balance_after":24675,"source":{"system":"sec-edgar","filing":"0000929638-24-002002","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963824002002/form4.xml","form_type":"4"}},{"id":1538012,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":91861,"kind":"person","name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","position":1,"cik":"0000903337","reported_name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common shares","published_at":"2024-04-22T17:22:10.000Z","date":"2024-04-22","kind":"sale","planned":false,"acquired":false,"shares":47854,"price":15,"value":717810.0,"ownership":{"direct":true},"balance_after":3036153,"source":{"system":"sec-edgar","filing":"0000950142-24-001171","document":"es240472025_4-engn.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/903337/000095014224001171/es240472025_4-engn.xml","form_type":"4"}},{"id":1538011,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":91861,"kind":"person","name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","position":1,"cik":"0000903337","reported_name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common shares","published_at":"2024-04-22T17:22:10.000Z","date":"2024-04-19","kind":"sale","planned":false,"acquired":false,"shares":100,"price":15,"value":1500.0,"ownership":{"direct":true},"balance_after":3084007,"source":{"system":"sec-edgar","filing":"0000950142-24-001171","document":"es240472025_4-engn.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/903337/000095014224001171/es240472025_4-engn.xml","form_type":"4"}},{"id":1538010,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":91861,"kind":"person","name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","position":1,"cik":"0000903337","reported_name":"FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common shares","published_at":"2024-04-22T17:22:10.000Z","date":"2024-04-18","kind":"sale","planned":false,"acquired":false,"shares":4575,"price":15.01,"value":68670.75,"ownership":{"direct":true},"balance_after":3084107,"source":{"system":"sec-edgar","filing":"0000950142-24-001171","document":"es240472025_4-engn.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/903337/000095014224001171/es240472025_4-engn.xml","form_type":"4"}},{"id":1561751,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37177,"kind":"person","name":"Zoth Lota S.","position":1,"cik":"0001278219","reported_name":"Zoth Lota S.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-25T20:01:23.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 1/3 on each of the first, second and third anniversaries of Ms. Zoth's date of appointment to the Board, which was December 18, 2023."}],"balance_after":40000,"derivative":{"exercise_price":17.8,"expiration_date":"2034-03-21","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000929638-24-001102","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278219/000092963824001102/form4.xml","form_type":"4"}},{"id":1565612,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-20T20:42:22.000Z","date":"2024-03-18","kind":"exercise","planned":false,"acquired":false,"shares":52940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested and exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This option was originally due to expire December 4, 2023, however prior to that date the expiration date was extended to 120 days following the filing of enGene Holdings Inc.'s Form S-8, which was filed February 27, 2024.  Accordingly, the option expiry date is June 26, 2024."}],"balance_after":0,"derivative":{"exercise_price":0.89,"underlying":"Common Shares","underlying_shares":52940},"source":{"system":"sec-edgar","filing":"0000929638-24-001069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963824001069/form4.xml","form_type":"4"}},{"id":1565611,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Common Shares","published_at":"2024-03-20T20:42:22.000Z","date":"2024-03-18","kind":"exercise","planned":false,"acquired":true,"shares":52940,"price":0.89,"value":47116.6,"ownership":{"direct":true},"balance_after":102873,"source":{"system":"sec-edgar","filing":"0000929638-24-001069","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963824001069/form4.xml","form_type":"4"}},{"id":1566966,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67864,"kind":"person","name":"Giguere Lee","position":1,"cik":"0001796465","reported_name":"Giguere Lee","relationship":{"officer":true,"officer_title":"Chief Legal Ofc. and Corp Secy"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-19T16:05:31.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on January 29, 2025, which is the first anniversary of Mr. Giguere's employment commencement date, with the remaining portion to vest monthly over the remaining three years."}],"balance_after":225000,"derivative":{"exercise_price":16.85,"expiration_date":"2034-03-15","underlying":"Common Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000929638-24-001049","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796465/000092963824001049/form4.xml","form_type":"4"}},{"id":1628360,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37163,"kind":"person","name":"BRUNK GERALD A","position":1,"cik":"0001380226","reported_name":"BRUNK GERALD A","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T21:20:30.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":155035,"price":10,"value":1550350.0,"ownership":{"direct":false,"nature":"See Notes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held by Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Mr. Brunk is an executive officer of certain entities controlling and/or managing the Lumira Entities. Mr. Brunk disclaims beneficial ownership of the Common Shares held by the Lumira Entities, except to the extent of his pecuniary interest therein, if any. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. (Continued in following footnote)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from prior footnote). Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":238851,"source":{"system":"sec-edgar","filing":"0000905148-24-000774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1380226/000090514824000774/form4.xml","form_type":"4"}},{"id":1628359,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37163,"kind":"person","name":"BRUNK GERALD A","position":1,"cik":"0001380226","reported_name":"BRUNK GERALD A","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T21:20:30.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":644965,"price":10,"value":6449650.0,"ownership":{"direct":false,"nature":"See Notes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held by Lumira Ventures IV, L.P. (\"Lumira IV\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Mr. Brunk is an executive officer of certain entities controlling and/or managing the Lumira Entities. Mr. Brunk disclaims beneficial ownership of the Common Shares held by the Lumira Entities, except to the extent of his pecuniary interest therein, if any. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. (Continued in following footnote)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"(Continued from prior footnote). Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":993651,"source":{"system":"sec-edgar","filing":"0000905148-24-000774","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1380226/000090514824000774/form4.xml","form_type":"4"}},{"id":1627945,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":1,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T16:20:10.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":155035,"price":10,"value":1550350.0,"ownership":{"direct":false,"nature":"Held by Lumira Ventures IV (International), L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed jointly by Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\"), Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the \"Reporting Person\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":238851,"source":{"system":"sec-edgar","filing":"0000905148-24-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702636/000090514824000773/form4.xml","form_type":"4"}},{"id":1627944,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":94039,"kind":"organization","name":"Lumira Capital Investment Management Inc.","position":1,"cik":"0001702636","reported_name":"Lumira Capital Investment Management Inc.","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-02-21T16:20:10.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":644965,"price":10,"value":6449650.0,"ownership":{"direct":false,"nature":"Held by Lumira Ventures IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is filed jointly by Lumira Ventures III, L.P. (\"Lumira III\"), Lumira Ventures III (International), L.P. (\"Lumira III Int'l\"), Lumira Ventures IV, L.P. (\"Lumira IV\"), Lumira Ventures IV (International), L.P. (\"Lumira IV Int'l\"), Merck Lumira Biosciences Fund, L.P. (\"Merck-Lumira\"), Merck Lumira Biosciences Fund (Quebec), L.P. (\"Merck-Lumira B\" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the \"Lumira Entities\"), Lumira Capital Investment Management Inc. (\"Lumira Mgmt\"), Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc. and Lumira GP Holdings Co. (collectively, the \"Reporting Person\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Gerald Brunk, a director of the Issuer, is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt and reports his beneficial ownership of these securities on a separate Form 4. Each of Lumira Ventures III GP, L.P., Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any."}],"balance_after":993651,"source":{"system":"sec-edgar","filing":"0000905148-24-000773","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702636/000090514824000773/form4.xml","form_type":"4"}},{"id":1723476,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":107771,"kind":"person","name":"BRYCE RICHARD PAUL","position":1,"cik":"0001553037","reported_name":"BRYCE RICHARD PAUL","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-04T17:55:37.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":153000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years."}],"balance_after":153000,"derivative":{"exercise_price":7.66,"expiration_date":"2033-11-30","underlying":"Common Shares","underlying_shares":153000},"source":{"system":"sec-edgar","filing":"0000929638-23-003341","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553037/000092963823003341/form4.xml","form_type":"4"}},{"id":1723452,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67903,"kind":"person","name":"Daws D. Ryan","position":1,"cik":"0001598602","reported_name":"Daws D. Ryan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-04T17:52:42.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":232000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests at 25% on the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years."}],"balance_after":232000,"derivative":{"exercise_price":7.66,"expiration_date":"2033-11-30","underlying":"Common Shares","underlying_shares":232000},"source":{"system":"sec-edgar","filing":"0000929638-23-003339","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598602/000092963823003339/form4.xml","form_type":"4"}},{"id":1750993,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67857,"kind":"person","name":"Nichols Alexander Julian","position":1,"cik":"0001998744","reported_name":"Nichols Alexander Julian","relationship":{"officer":true,"officer_title":"Pres. & Chief Operating Ofc."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:59.000Z","date":"2023-07-07","kind":"grant","planned":false,"acquired":true,"shares":101924,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 564,739 common shares of enGene.  At the grant date, 12% of the option vested immediately, with the remaining portion to vest equally over 48 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 564,739 common shares of enGene.  At the grant date, 12% of the option vested immediately, with the remaining portion to vest equally over 48 months."}],"balance_after":101924,"derivative":{"exercise_price":4.25,"expiration_date":"2033-07-07","underlying":"Common Shares","underlying_shares":101924},"source":{"system":"sec-edgar","filing":"0000929638-23-002991","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002991/form4.xml","form_type":"4"}},{"id":1750992,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67857,"kind":"person","name":"Nichols Alexander Julian","position":1,"cik":"0001998744","reported_name":"Nichols Alexander Julian","relationship":{"officer":true,"officer_title":"Pres. & Chief Operating Ofc."}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:59.000Z","date":"2023-02-18","kind":"grant","planned":false,"acquired":true,"shares":177935,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 985,899 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 985,899 common shares of enGene."}],"balance_after":177935,"derivative":{"exercise_price":1.52,"expiration_date":"2033-02-18","underlying":"Common Shares","underlying_shares":177935},"source":{"system":"sec-edgar","filing":"0000929638-23-002991","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002991/form4.xml","form_type":"4"}},{"id":1750991,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2023-07-07","kind":"grant","planned":false,"acquired":true,"shares":185222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 1,026,277 common shares of enGene.  This option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 1,026,277 common shares of enGene.  This option is fully vested."}],"balance_after":185222,"derivative":{"exercise_price":4.25,"expiration_date":"2033-07-07","underlying":"Common Shares","underlying_shares":185222},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750990,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":2255,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 12,500 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 12,500 common shares of enGene."}],"balance_after":2255,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":2255},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750989,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":155472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 861,441 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 861,441 common shares of enGene."}],"balance_after":155472,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":155472},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750988,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2020-12-14","kind":"grant","planned":false,"acquired":true,"shares":1266,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 7,020 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 7,020 common shares of enGene."}],"balance_after":1266,"derivative":{"exercise_price":0.88,"expiration_date":"2030-12-14","underlying":"Common Shares","underlying_shares":1266},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750987,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2018-03-16","kind":"grant","planned":false,"acquired":true,"shares":36618,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 202,897 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 202,897 common shares of enGene."}],"balance_after":36618,"derivative":{"exercise_price":0.88,"expiration_date":"2028-03-16","underlying":"Common Shares","underlying_shares":36618},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750986,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2016-01-11","kind":"grant","planned":false,"acquired":true,"shares":22860,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 126,667 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 126,667 common shares of enGene."}],"balance_after":22860,"derivative":{"exercise_price":0.88,"expiration_date":"2026-01-11","underlying":"Common Shares","underlying_shares":22860},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750985,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2015-05-21","kind":"grant","planned":false,"acquired":true,"shares":28876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 160,000 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 160,000 common shares of enGene."}],"balance_after":28876,"derivative":{"exercise_price":0.88,"expiration_date":"2025-05-21","underlying":"Common Shares","underlying_shares":28876},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750984,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:10:33.000Z","date":"2013-12-04","kind":"grant","planned":false,"acquired":true,"shares":52940,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 293,333 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 293,333 common shares of enGene."}],"balance_after":52940,"derivative":{"exercise_price":0.88,"expiration_date":"2023-12-04","underlying":"Common Shares","underlying_shares":52940},"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1750983,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":67858,"kind":"person","name":"CHEUNG ANTHONY TZEYEW","position":1,"cik":"0001998684","reported_name":"CHEUNG ANTHONY TZEYEW","relationship":{"officer":true,"officer_title":"Chief Technology Officer"}}],"security":"Common Shares","published_at":"2023-11-02T20:10:33.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":49933,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Reflects Common Shares acquired pursuant to the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects Common Shares acquired pursuant to the Business Combination."}],"balance_after":49933,"source":{"system":"sec-edgar","filing":"0000929638-23-002990","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002990/form4.xml","form_type":"4"}},{"id":1751102,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2023-07-07","kind":"grant","planned":false,"acquired":true,"shares":512826,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene.  This option is fully vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"7. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 2,841,461 common shares of enGene.  This option is fully vested."}],"balance_after":512826,"derivative":{"exercise_price":4.25,"expiration_date":"2033-07-07","underlying":"Common Shares","underlying_shares":512826},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751101,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":10906,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"6. This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 60,429 common shares of enGene."}],"balance_after":10906,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":10906},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751100,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":524544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 2,906,386 common shares of enGene."}],"balance_after":524544,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":524544},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751099,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2019-07-30","kind":"grant","planned":false,"acquired":true,"shares":30939,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 171,429 common shares of enGene."}],"balance_after":30939,"derivative":{"exercise_price":0.88,"expiration_date":"2029-07-30","underlying":"Common Shares","underlying_shares":30939},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1751098,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":38083,"kind":"person","name":"Hanson Jason David","position":1,"cik":"0001368586","reported_name":"Hanson Jason David","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:58.000Z","date":"2018-07-09","kind":"grant","planned":false,"acquired":true,"shares":137051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 759,374 common shares of enGene."}],"balance_after":137051,"derivative":{"exercise_price":0.88,"expiration_date":"2028-07-09","underlying":"Common Shares","underlying_shares":137051},"source":{"system":"sec-edgar","filing":"0000929638-23-002989","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368586/000092963823002989/form4.xml","form_type":"4"}},{"id":1750982,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":108645,"kind":"person","name":"Sullivan James Crowley","position":1,"cik":"0001998773","reported_name":"Sullivan James Crowley","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:31.000Z","date":"2023-07-07","kind":"grant","planned":false,"acquired":true,"shares":118509,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"4. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 656,637 common shares of enGene.  At the grant date, 30% of the option vested immediately, with the remaining portion to vest equally over 48 months."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"4. This option was granted on July 7, 2023 on the condition it is not exercisable unless and until (i) the Business Combination Agreement has been completed and (ii) an effective registration statement for the New enGene shares underlying such granted options has been filed. This option was received in the Business Combination in exchange for an option to purchase 656,637 common shares of enGene.  At the grant date, 30% of the option vested immediately, with the remaining portion to vest equally over 48 months."}],"balance_after":118509,"derivative":{"exercise_price":4.25,"expiration_date":"2033-07-07","underlying":"Common Shares","underlying_shares":118509},"source":{"system":"sec-edgar","filing":"0000929638-23-002988","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002988/form4.xml","form_type":"4"}},{"id":1750981,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":108645,"kind":"person","name":"Sullivan James Crowley","position":1,"cik":"0001998773","reported_name":"Sullivan James Crowley","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:09:31.000Z","date":"2022-03-18","kind":"grant","planned":false,"acquired":true,"shares":88901,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 492,582 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 492,582 common shares of enGene."}],"balance_after":88901,"derivative":{"exercise_price":0.88,"expiration_date":"2032-03-18","underlying":"Common Shares","underlying_shares":88901},"source":{"system":"sec-edgar","filing":"0000929638-23-002988","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1980845/000092963823002988/form4.xml","form_type":"4"}},{"id":1751117,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:08:59.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":12001,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene."}],"balance_after":12001,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":12001},"source":{"system":"sec-edgar","filing":"0000929638-23-002987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963823002987/form4.xml","form_type":"4"}},{"id":1751116,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:08:59.000Z","date":"2021-08-20","kind":"grant","planned":false,"acquired":true,"shares":14205,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene."}],"balance_after":14205,"derivative":{"exercise_price":0.88,"expiration_date":"2031-08-20","underlying":"Common Shares","underlying_shares":14205},"source":{"system":"sec-edgar","filing":"0000929638-23-002987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963823002987/form4.xml","form_type":"4"}},{"id":1751115,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:08:59.000Z","date":"2020-12-14","kind":"grant","planned":false,"acquired":true,"shares":12032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene."}],"balance_after":12032,"derivative":{"exercise_price":0.88,"expiration_date":"2030-12-14","underlying":"Common Shares","underlying_shares":12032},"source":{"system":"sec-edgar","filing":"0000929638-23-002987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963823002987/form4.xml","form_type":"4"}},{"id":1751114,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:08:59.000Z","date":"2018-03-16","kind":"grant","planned":false,"acquired":true,"shares":4123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene."}],"balance_after":4123,"derivative":{"exercise_price":0.88,"expiration_date":"2028-03-16","underlying":"Common Shares","underlying_shares":4123},"source":{"system":"sec-edgar","filing":"0000929638-23-002987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963823002987/form4.xml","form_type":"4"}},{"id":1751113,"issuer":{"id":6638,"kind":"organization","name":"enGene Therapeutics Inc.","symbol":"ENGN"},"owners":[{"id":37170,"kind":"person","name":"Glickman Richard M","position":1,"cik":"0001352637","reported_name":"Glickman Richard M","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-02T20:08:59.000Z","date":"2017-06-15","kind":"grant","planned":false,"acquired":true,"shares":3188,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 31, 2023 (the \"Closing Date\"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the \"Business Combination Agreement\"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (\"FEAC\"), enGene Inc., a corporation incorporated under the laws of Canada (\"enGene\"), and enGene Holdings Inc. (the \"Issuer\" or \"New enGene\"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene.  The transactions contemplated by the Business Combination Agreement are referred to herein as the \"Business Combination\"."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer (\"Common Shares\") for each share of enGene held by them immediately prior to the Closing Date.  Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene."}],"balance_after":3188,"derivative":{"exercise_price":0.88,"expiration_date":"2027-06-15","underlying":"Common Shares","underlying_shares":3188},"source":{"system":"sec-edgar","filing":"0000929638-23-002987","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352637/000092963823002987/form4.xml","form_type":"4"}}],"next_cursor":"2023-11-02T20:08:59.000000Z,1751113"}